More targets, more pathways and more clues for mutant p53

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Garritano, S ^a   Inga, A ^b   Gemignani, F ^a   Landi, S ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF TRENTO   (Italy)

Author keywords

Microarray; P53; Target genes

Indexed keywords

ARGININE; ASPARTIC ACID; GLUTAMIC ACID; PROTEIN P53;

CELL DIFFERENTIATION; COMPUTER MODEL; GENE EXPRESSION; GENE TARGETING; HUMAN; INTRACELLULAR SIGNALING; MISSENSE MUTATION; MUTANT; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; TRANSCRIPTION INITIATION; XENOBIOTIC METABOLISM;

EID: 84880539918     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.15     Document Type: Review

References (96)

1. Coutts AS, La TN. The p53 response during DNA damage: impact of transcriptional cofactors. Biochem Soc Symp 2006; 73: 181-189.
2. Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2011; 2: e164.
3. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-412.
4. Lane D, Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2010; 2: a000893.
5. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
6. Wiesmuller L. Genetic stabilization by p53 involves growth regulatory and repair pathways. J Biomed Biotechnol 2001; 1: 7-10.
7. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A et al. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a proinvasive secretome. Oncotarget 2011; 2: 1203-1217.
8. Wang B, Xiao Z, Ko HL, Ren EC. The p53 response element and transcriptional repression. Cell Cycle 2010; 9: 870-879.
9. Li FP, Fraumeni Jr. JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48: 5358-5362.
10. Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G et al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res 2013; 41: D962-D969.
11. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.
12. Soussi T, Kato S, Levy PP, Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005; 25: 6-17.
13. Achatz MI, Hainaut P, shton-Prolla P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol 2009; 10: 920-925.
14. Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, Schmidt S et al. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 1993; 5: 124-129.
15. Resnick MA, Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 2003; 100: 9934-9939.
16. Menendez D, Inga A, Resnick MA. The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol 2006; 26: 2297-2308.
17. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996; 15: 827-838.
18. Acin S, Li Z, Mejia O, Roop DR, El-Naggar AK, Caulin C. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol 2011; 225: 479-489.
19. Iwakuma T, Lozano G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 2007; 26: 2177-2184.
20. Smardova J, Smarda J, Koptikova J. Functional analysis of p53 tumor suppressor in yeast. Differentiation 2005; 73: 261-277.
21. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-713.
22. Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, Blandino G. Oncogenomic approaches in exploring gain of function of mutant p53. Curr Genomics 2008 9: 200-207.
23. Lozano G. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 2007; 17: 66-70.
24. Peart MJ, Prives C. Mutant p53 gain of function: the NF-Y connection. Cancer Cell 2006; 10: 173-174.
25. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165.
26. Song H, Xu Y. Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways. Cell Cycle 2007; 6: 1570-1573.
27. Strano S, Dell'Orso S, Di AS, Fontemaggi G, Sacchi A, Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene 2007; 26: 2212-2219.
28. Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M et al. Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death Differ 2012; 19: 180-183.
29. Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T. The UMD TP53 database and website: update and revisions. Hum Mutat 2006 27: 14-20.
30. Maccari G, Gemignani F, Landi S. COMPASSS (COMplex PAttern of Sequence Search Software), a simple and effective tool for mining complex motifs in whole genomes. Bioinformatics 2010; 26: 1777-1778.
31. Jordan JJ, Menendez D, Inga A, Noureddine M, Bell DA, Resnick MA. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53. PLoS Genet 2008; 4: e1000104.
32. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009; 9: 724-737.
33. Huang dW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
34. Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M et al. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ 2012; 19: 1992-2002.
35. Johnson RA, Ince TA, Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 2001; 276: 27716-27720.
36. Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM, Latchman DS. p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. J Biol Chem 1999; 274: 15237-15244.
37. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-3257.
38. Rinn JL, Huarte M. To repress or not to repress: this is the guardian's question. Trends Cell Biol 2011; 21: 344-353.
39. Bohlig L, Rother K. One function-multiple mechanisms: the manifold activities of p53 as a transcriptional repressor. J Biomed Biotechnol 2011; 2011: 464916.
40. Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Korner S, Wang W et al. Wildtype p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci USA 2011; 108: 14240-14245.
41. Kobayashi K, Era T, Takebe A, Jakt LM, Nishikawa S. ARID3B induces malignant transformation of mouse embryonic fibroblasts and is strongly associated with malignant neuroblastoma. Cancer Res 2006; 66: 8331-8336.
42. Maltepe E, Keith B, Arsham AM, Brorson JR, Simon MC. The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia. Biochem Biophys Res Commun 2000; 273: 231-238.
43. Kanojia D, Zhou W, Zhang J, Jie C, Lo PK, Wang Q et al. Proteomic profiling of cancer stem cells derived from primary tumors of HER2/Neu transgenic mice. Proteomics 2012; 12: 3407-3415.
44. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K et al. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004; 119: 529-542.
45. Epsztejn S, Glickstein H, Picard V, Slotki IN, Breuer W, Beaumont C et al. H-ferritin subunit overexpression in erythroid cells reduces the oxidative stress response and induces multidrug resistance properties. Blood 1999; 94: 3593-3603.
46. Liu X, Madhankumar AB, Slagle-Webb B, Sheehan JM, Surguladze N, Connor JR. Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. Cancer Res 2011; 71: 2240-2249.
47. Christiansen A, Dyrskjot L. The functional role of the novel biomarker karyopherin alpha 2 (KPNA2) in cancer. Cancer Lett 2013; 331: 18-23.
48. Aranda V, Nolan ME, Muthuswamy SK. Par complex in cancer: a regulator of normal cell polarity joins the dark side. Oncogene 2008; 27: 6878-6887.
49. Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009; 14: 597-606.
50. Reinhardt HC, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 2012; 28: 128-136.
51. Budanov AV, Lee JH, Karin M. Stressin' Sestrins take an aging fight. EMBO Mol Med 2010; 2: 388-400.
52. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 2010; 107: 7455-7460.
53. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA 2010; 107: 7461-7466.
54. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008; 10: 611-618.
55. Kawauchi K, Araki K, Tobiume K, Tanaka N. Activated p53 induces NF-kappaB DNA binding but suppresses its transcriptional activation. Biochem Biophys Res Commun 2008; 372: 137-141.
56. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004; 64: 2627-2633.
57. Kulawiec M, Ayyasamy V, Singh KK. p53 regulates mtDNA copy number and mitocheckpoint pathway. J Carcinog 2009; 8: 8.
58. Lebedeva MA, Eaton JS, Shadel GS. Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. Biochim Biophys Acta 2009; 1787: 328-334.
59. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-6752.
60. Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N et al. p53, a novel regulator of lipid metabolism pathways. J Hepatol 2012; 56: 656-662.
61. Wu W, Zhao S. Metabolic changes in cancer: beyond the Warburg effect. Acta Biochim Biophys Sin (Shanghai) 2013; 45: 18-26.
62. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O et al. p53 regulates mitochondrial respiration. Science 2006; 312: 1650-1653.
63. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 2009; 9: 691-700.
64. Liu W, Phang JM. Proline dehydrogenase (oxidase) in cancer. Biofactors 2012; 38: 398-406.
65. Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF et al. Modulation of gene expression by tumor-derived p53 mutants. Cancer Res 2004; 64: 7447-7454.
66. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005; 65: 10280-10288.
67. Liu DP, Song H, Xu Y. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 2010; 29: 949-956.
68. Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008; 45: 535-538.
69. Solomon H, Madar S, Rotter V. Mutant p53 gain of function is interwoven into the hallmarks of cancer. J Pathol 2011; 225: 475-478.
70. Ushio Y, Tada K, Shiraishi S, Kamiryo T, Shinojima N, Kochi M et al. Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. Front Biosci 2003; 8: e281-e288.
71. van Slooten HJ, van De Vijver MJ, Borresen AL, Eyfjord JE, Valgardsdottir R, Scherneck S et al. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma. J Pathol 1999; 189: 504-513.
72. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
73. Kremenetskaya OS, Logacheva NP, Baryshnikov AY, Chumakov PM, Kopnin BP. Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells. Oncol Res 1997; 9: 155-166.
74. Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001; 277: 15-30.
75. Lin J, Teresky AK, Levine AJ. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 1995; 10: 2387-2390.
76. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 6788-6793.
77. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2012; 32: 3286-3295.
78. Donzelli S, Fontemaggi G, Fazi F, Di AS, Padula F, Biagioni F et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012; 19: 1038-1048.
79. Vaughan CA, Frum R, Pearsall I, Singh S, Windle B, Yeudall A et al. Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem Biophys Res Commun 2012; 428: 6-10.
80. Vaughan CA, Singh S, Windle B, Sankala HM, Graves PR, Andrew YW et al. p53 mutants induce transcription of NF-kappaB2 in H1299 cells through CBP and STAT binding on the NF-kappaB2 promoter and gain of function activity. Arch Biochem Biophys 2012; 518: 79-88.
81. Gurtner A, Starace G, Norelli G, Piaggio G, Sacchi A, Bossi G. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem 2010; 285: 14160-14169.
82. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268-1286.
83. Davison TS, Vagner C, Kaghad M, Ayed A, Caput D, Arrowsmith CH. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem 1999; 274: 18709-18714.
84. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin Jr WG. Chemosensitivity linked to p73 function. Cancer Cell 2003; 3: 403-410.
85. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 2011; 18: 1487-1499.
86. Strano S, Rossi M, Fontemaggi G, Munarriz E, Soddu S, Sacchi A et al. From p63 to p53 across p73. FEBS Lett 2001; 490: 163-170.
87. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002; 277: 18817-18826.
88. Li CQ, Robles AI, Hanigan CL, Hofseth LJ, Trudel LJ, Harris CC et al. Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res 2004; 64: 3022-3029.
89. O'Farrell TJ, Ghosh P, Dobashi N, Sasaki CY, Longo DL. Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res 2004; 64: 8199-8207.
90. Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M et al. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle 2008; 7: 1870-1879.
91. Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia 2008; 10: 450-461.
92. Mizuarai S, Yamanaka K, Kotani H. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res 2006; 66: 6319-6326.
93. Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE et al. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate 2005; 65: 375-389.
94. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M et al. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 2004; 64: 8318-8327.
95. Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A et al. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 2004; 23: 4430-4443.
96. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF et al. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 2005; 25: 10097-10110.